In the treatment experiments described in this report, however, we found at the dose given, 0.5 mg/kg (~12 μg/mouse), CD6-ADC significantly suppressed the development of uveitis (Figure 3A) after the adoptive transfer of preactivated uveitogenic T cells, but the same dose of the “naked” anti-CD6 mAb only delayed the development of uveitis and moderately attenuated retina inflammation in the treated mice within the first week of uveitis development. The gene discussed is CD6; the disease is uveitis.